The quiet winner here was a short burst of hormone therapy - and in a breast cancer world that often reaches for chemo first, that’s a bit like the bench player draining the game-winning shot. Now let’s rewind and see why nearly 8,000 patients made that result worth paying attention to.

A quick stress test for estrogen-driven tumors

This new analysis from the WSG ADAPT-HR+/HER2- and ADAPTcycle trials looked at a simple but sneaky-smart question: if you give hormone receptor-positive, HER2-negative early breast cancer a short 2- to 4-week course of endocrine therapy before surgery, can you tell which tumors are likely to behave and which ones are more likely to be trouble?

That “stress test” idea matters because not all breast cancers that wear the same label act the same way. Some are heavily dependent on estrogen signals - cut off the hormonal supply, and they calm down fast. Others act like they read the memo and chose chaos anyway.

The researchers studied 7,914 patients and focused on Ki-67, a marker of cell proliferation. Think of Ki-67 as a rough speedometer for how frantically tumor cells are dividing. If Ki-67 drops to 10% or less after a short run of endocrine therapy, that counts as a good response. In plain English: the tumor seems hormonally dependent and may not need the oncology equivalent of bringing a flamethrower to toast a bagel.

The underdog move: less treatment, smarter timing

This is where the study gets interesting. The usual fear in cancer care is undertreating someone who actually needed more. Fair fear. Nobody wants to be casual about a disease that treats boundaries like suggestions.

But overtreatment has its own costs. Chemotherapy saves lives, yes, but it also brings side effects that can hit hard and linger. So if doctors can identify people who might do very well with endocrine therapy-based strategies and avoid chemo, that’s not a minor quality-of-life tweak. That’s a big deal.

And this paper suggests they can do that better by combining:
- short preoperative endocrine therapy
- Ki-67 response
- genomic testing, especially recurrence score (RS)
- classic clinical factors like age, nodal status, and baseline tumor biology

That’s less fortune-telling, more informed scouting report.

Aromatase inhibitors came to play

One of the clearest findings was that aromatase inhibitors (AIs) outperformed tamoxifen for this short-term response readout.

In both trials, endocrine response rates were much higher with AIs:
- ADAPT-HR+/HER2-: 81.4% with AI vs 40.1% with tamoxifen
- ADAPTcycle: 76.7% with AI vs 34.7% with tamoxifen

That is not a subtle difference. That is “one team showed up in sneakers, the other in hiking boots” territory.

For premenopausal patients, adding ovarian function suppression (OFS) mattered a lot. Young patients who received GnRH suppression plus an AI had response rates similar to postmenopausal patients. That’s a pretty important twist, because it suggests the gap between younger and older patients may not be some immutable biological curse. It may be, at least in part, about picking the right endocrine setup.

Who responded best?

The study’s logistic models found several predictors of better endocrine response:

• AI use - with OFS in premenopausal patients
• Age over 50
• Lower baseline Ki-67
• Lower recurrence score
• Higher estrogen receptor expression
• Somewhat surprisingly, higher HER2 expression by Oncotype DX also associated with response in this setting

The general pattern makes sense. Tumors that look more classically hormone-driven were more likely to settle down when estrogen signaling got blocked.

If that sounds obvious, welcome to oncology, where the obvious still needs 7,914 patients and a mountain of statistics before anyone is allowed to exhale.

Why doctors care about a 2-week detour before surgery

Short preoperative endocrine therapy is appealing because it gives doctors real-time biological feedback. Instead of treating based only on what a tumor looked like at diagnosis, you get to see how it reacts when you actually interfere with its fuel source.

That’s useful because breast cancer treatment has been moving toward de-escalation when safe and escalation when needed. A quick endocrine “test drive” may help sort patients more precisely.

The outcome data here support that strategy. In the ADAPT-HR+/HER2- cohort, 5-year distant disease-free survival was better in endocrine responders than nonresponders, and responders even did well compared with some chemotherapy-treated higher-risk groups. The headline message is not “chemo is obsolete” - absolutely not. It’s that some patients with luminal early breast cancer may be getting flagged as stronger candidates for chemo than they really are.

And if a short course of endocrine therapy plus molecular profiling can spare some of them that ordeal, that’s the kind of underdog win worth cheering.

The catch, because there is always a catch

Before we start acting like every tumor can be tamed with a two-week endocrine timeout, a few caveats.

Ki-67 is useful, but it has long had a reputation for being a bit of a diva in pathology - valuable, but fussy about measurement and interpretation. Also, these treatment decisions rely on integrating multiple factors, not one magic number. This is a strategy for refining judgment, not replacing it.

And while these data are large and clinically relevant, the real-world challenge is implementation. Doctors need reliable testing, consistent pathology, access to genomic assays, and enough confidence to actually de-escalate treatment when the evidence says they can.

Medicine, like every group project, is not limited by ideas nearly as much as by logistics.

The bigger picture

This paper adds to a growing push in breast cancer care: stop treating all HR-positive/HER2-negative disease like one giant beige blob. Some tumors are exquisitely hormone-sensitive. Some are less so. A short endocrine trial helps expose that difference early.

That may mean more patients can avoid chemotherapy without compromising outcomes, especially when response data line up with favorable genomic signals. For a field that has spent decades trying to personalize treatment, this is personalization with its sleeves rolled up - practical, fast, and tied to an actual biological reaction.

And honestly, I’m always going to root for the scrappy strategy that says, “What if we learned more before throwing the whole medicine cabinet at the problem?”

References

1. Gluz O, Nitz U, Christgen M, et al. Clinical and molecular biomarkers for prediction of endocrine response after short preoperative endocrine therapy in the WSG ADAPT-HR+/HER2- and ADAPTcycle trials (N = 7914). Ann Oncol. 2026. doi:10.1016/j.annonc.2026.04.007

2. Spring LM, Gupta A, Reynolds KL, et al. Neoadjuvant endocrine therapy for estrogen receptor-positive breast cancer: a systematic review and meta-analysis. JAMA Oncol. 2016;2(11):1477-1486. doi:10.1001/jamaoncol.2016.1897

3. Harbeck N, Gluz O, Christgen M, et al. De-escalation strategies in HR-positive, HER2-negative early breast cancer guided by genomic assays and response biomarkers have become a major clinical focus in recent years. For broader context on individualized early breast cancer treatment, see: Loibl S, Poortmans P, Morrow M, Denkert C, Curigliano G. Breast cancer. Lancet. 2021;397(10286):1750-1769. doi:10.1016/S0140-6736(20)32381-3

4. Johnston SRD, Harbeck N, Hegg R, et al. Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR-positive, HER2-negative, node-positive early breast cancer. J Clin Oncol. 2020;38(34):3987-3998. doi:10.1200/JCO.20.02514

5. Early Breast Cancer Trialists’ Collaborative Group. Aromatase inhibitors versus tamoxifen in premenopausal women with estrogen receptor-positive early-stage breast cancer treated with ovarian suppression: patient-level meta-analysis of 7,030 women from four randomised trials. Lancet Oncol. 2022;23(3):382-392. doi:10.1016/S1470-2045(21)00758-0

Disclaimer: The image accompanying this article is for illustrative purposes only and does not depict actual experimental results, data, or biological mechanisms.